Psoriatic Arthritis

The Pharmacy Times® Psoriatic Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
Long-Lasting Inhibition of Radiographic Progression Shown with Secukinumab for Psoriatic Arthritis
Treatment with secukinumab (Cosentyx, Novartis) inhibited radiographic progression in most patients with psoriatic arthritis over 2 years in a phase 3 trial.
June 21 Pharmacy Week in Review: Study Links BMI and Psoriatic Arthritis Severity, Survival Disparities Growing Among Young Patients with Cancer
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Tildrakizumab Demonstrates Efficacy in Treating Patients with Psoriatic Arthritis
Study results demonstrate superior efficacy and comparable safety for tildrakizumab versus a placebo in patients with psoriatic arthritis.
Psoriasis Patients Without Psoriatic Arthritis Benefit More From Methotrexate
A study of methotrexate in patients with psoriasis found that the immunosuppressive drug was more effective in patients without psoriatic arthritis than those with the added condition.
Bimekizumab Shows Improvement in Psoriatic Arthritis Across Joint, Skin Manifestations
Phase 2b study results show durable responses rates and symptom improvement in patients with psoriatic arthritis.
Updated Secukinumab Label to Include Evidence for Treatment of Psoriatic Arthritis
The updated label includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.
FDA OKs Secukinumab Label Update for Psoriatic Arthritis
The label update includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.
AbbVie Seeks Approval for Moderate to Severe Plaque Psoriasis Drug
Risankizumab shows promise as an important treatment option for people living with plaque psoriasis.
How Will the Biosimilar Market Change in 2018?
Ron Lanton III, Esq, President, True North Political Solutions, makes predictions about how dealings with biosimilars may change in 2018.
Tofacitinib Approved for Active Psoriatic Arthritis
Tofacitinib (Xeljanz/Xeljanz XR) improves disease severity for patients with psoriatic arthritis.
+ Load More